LEADER 01601nam--2200457---450- 001 990002839260203316 005 20061127090517.0 010 $a978-88-08-09145-1 035 $a000283926 035 $aUSA01000283926 035 $a(ALEPH)000283926USA01 035 $a000283926 100 $a20061127d2006----km-y0itay50------ba 101 1 $aita 102 $aIT 105 $aa|||z|||001yy 200 1 $aStruttura e progetto dei calcolatori$el'interfaccia hardware-software$fDavid A. Patterson, John L. Hennessy$g[traduzione di Matteo Monchiero, Gianluca Palermo, Oreste Villa] 205 $a2. ed. condotta sulla 3. ed. americana 210 $aBologna$cZanichelli$d2006 215 $aXIV, 554 p.$cill.$d27 cm$e1 CD-ROM 454 1$12001$aComputer organization and design$915210 606 0 $aElaboratori elettronici$xStruttura 606 0 $aMicroelaboratori elettronici$xStruttura 606 0 $aElaboratori elettronici$xProgettazione 606 0 $aMicroelaboratori elettronici$xProgettazione 676 $a004.22 700 1$aPATTERSON,$bDavid A.$08005 701 1$aHENNESSY,$bJohn L.$09509 702 1$aMONCHIERO,$bMatteo 702 1$aPALERMO,$bGianluca 702 1$aVILLA,$bOreste 801 0$aIT$bsalbc$gISBD 912 $a990002839260203316 951 $a004.22 PAT$b19797 Ing.$c004.22$d00119264 951 $a004.22 PAT$b19798 Ing.$c004.22$d00119265 951 $a004.22 PAT$b19799 Ing.$c004.22$d00119266 959 $aBK 969 $aTEC 979 $aANNAMARIA$b90$c20061127$lUSA01$h0905 996 $aComputer organization and design$915210 997 $aUNISA LEADER 05721nam 2201441z- 450 001 9910639995103321 005 20231214132827.0 010 $a3-0365-6165-X 035 $a(CKB)5470000001633402 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/95900 035 $a(EXLCZ)995470000001633402 100 $a20202301d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCurrent Insights on Lipid-Based Nanosystems 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (368 p.) 311 $a3-0365-6166-8 330 $aLipid-based nanosystems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), cationic lipid nanoparticles, nanoemulsions, and liposomes, have been extensively studied to improve drug delivery through different administration routes. The main advantages of these systems are their ability to protect, transport, and control the release of lipophilic and hydrophilic molecules (either small-molecular-weight molecules or macromolecules); the use of generally recognized as safe (GRAS) excipients that minimize the toxicity of the formulations; and the possibility to modulate pharmacokinetics and enable the site-specific delivery of encapsulated payloads. In addition, the versatility of lipid-based nanosystems has further been demonstrated for the delivery of vaccines, the protection of active cosmetic ingredients, and the improvement of moisturizing properties of cosmetic formulations.Lipid-based nanosystems are well established and there are already different commercially approved formulations for various human disorders. This success has paved the way for the diversification of the pipeline of development, to address unmet medical needs for several indications, such as cancer, neurological disorders, and autoimmune, genetic, and infectious diseases.This Special Issue aims to update readers on the latest research on lipid-based nanosystems, both at the preclinical and clinical levels. A series of 15 articles (six reviews and nine studies) is presented, with authors from 12 different countries, showing the globality of the investigations that are being carried out in this area. 606 $aTechnology: general issues$2bicssc 610 $aEchinococcus granulosus 610 $ascolicidal 610 $ananoliposome 610 $ajuglone 610 $aapoptotic activity 610 $ahydrogel 610 $aSLNs 610 $anose-to-brain delivery 610 $amucoadhesion 610 $aquality by design 610 $aantioxidant activity 610 $anasal administration 610 $ananostructured lipid carriers 610 $asolid lipid nanoparticles 610 $ain vitro cell cultures 610 $a3D nasal casts 610 $alung cancer 610 $atargeted drug delivery 610 $alipid-based nanocarriers 610 $apulmonary delivery 610 $adry powder inhalers 610 $aaerosols 610 $aliposomes 610 $ananoemulsions 610 $ananotechnology 610 $abiologically active compounds 610 $adermal drug delivery 610 $apolyphenols 610 $aphytophenols 610 $askin permeation 610 $achemotherapy 610 $aradiotherapy 610 $aactive targeting 610 $apassive targeting 610 $atumor 610 $aimmunoconjugate 610 $atraditional liposome 610 $astealth liposome 610 $atriggered release 610 $alimitations of liposomes 610 $adrug transfer 610 $ain vitro release 610 $acolloidal drug carriers 610 $alipid nanoparticles 610 $ahydrogel beads 610 $acholesteryl nonanoate 610 $abovine serum albumin 610 $askin diseases 610 $alipid-based nanosystems 610 $acream 610 $aointment 610 $agel 610 $apH-sensitive 610 $aliposome 610 $aimidazole 610 $aanticancer 610 $adrug delivery 610 $amulticellular spheroids 610 $adapagliflozin 610 $aBox-Behnken design 610 $aFTIR 610 $aDSC 610 $aXRD 610 $aSEM 610 $aAFM 610 $ain vitro Franz diffusion cells 610 $alipid-based nanoparticles 610 $ananocarrier 610 $asurface charge 610 $adelivery systems 610 $achronic treatment 610 $amice 610 $aanti-oxidant activity 610 $ahepatoprotective effect 610 $aphospholipid 610 $aphytosomes 610 $aSilymarin 610 $aColorectal Cancer 610 $aNiosomes 610 $aOxaliplatin 610 $aPaclitaxel 610 $ad-?-tocopheryl polyethylene glycol 1000 succinate (TPGS) 610 $atherapeutic nucleic acids 610 $aschizophrenia 610 $aquetiapine fumarate 610 $aglycerosomes 610 $acentral composite rotatable design 610 $abioavailability 610 $apharmacokinetic 615 7$aTechnology: general issues 700 $aSilva$b Ana Catarina$4edt$01301848 702 $aMoreira$b Joa?o$4edt 702 $aSousa Lobo$b Jose? Manuel$4edt 702 $aSilva$b Ana Catarina$4oth 702 $aMoreira$b Joa?o$4oth 702 $aSousa Lobo$b Jose? Manuel$4oth 906 $aBOOK 912 $a9910639995103321 996 $aCurrent Insights on Lipid-Based Nanosystems$93026021 997 $aUNINA